This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.
Galapagos NV announced that today it has initiated Phase I clinical development of its integrin receptor antagonist (IRA), GLPG0187. This is the second small molecule therapeutic from Galapagos' internal drug discovery program to enter the clinic in 2009. Candidate drug GLPG0187 could offer a promising new therapeutic approach for treating cancer patients. Initial development will focus on bone metastases from prostate and breast cancer.
We care about your feedback. Let us know how we can improve your CancerCompass experience.